Fiche publication
Date publication
octobre 2025
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Grande E, Bellmunt J, Hussain SA, Al Mansour MM, Bamias A, Barthélémy P, Benjamin DJ, Blais N, Bourlon MT, Castellano D, Danchaivijitr P, Fernandez Lazzaro M, Giannatempo P, Guerrero-Ramos F, Iacovelli R, Ivanyi P, Jung EH, Kanesvaran R, Manneh R, Marinho JC, Matsubara N, Merseburger AS, Mukherji D, Park CH, Tran B, da Trindade KM, Ürün Y, Kamat AM, Birtle AJ
Lien Pubmed
Résumé
Enfortumab vedotin combined with pembrolizumab (EV-P) has become the new standard first-line therapy for patients with advanced urothelial carcinoma (aUC), based on its superior efficacy over platinum-based chemotherapy. As this regimen is increasingly adopted in routine care, treatment decisions may often occur in sites without dedicated genitourinary oncology expertise. This global survey aimed to explore how physicians perceive clinical factors that may influence the safe and effective use of EV-P in daily practice.
Mots clés
Urothelial carcinoma, criteria, enfortumab vedotin, individualization, systemic treatment
Référence
Oncologist. 2025 10 6;:
